Ultragenyx Pharmaceutical Inc. $RARE Shares Bought by Trexquant Investment LP

Key Points

• Trexquant Investment LP increased its ownership in Ultragenyx Pharmaceutical by 71.5% in Q1, holding a total of 268,666 shares, valued at approximately $9.7 million.
• Ultragenyx recently reported revenues of $166.50 million for the quarter, surpassing estimates and showing a 13.2% year-over-year increase, with earnings per share beating expectations by $0.10.
• The stock received mixed ratings from analysts, with a consensus rating of "Moderate Buy" and an average price target of $81.50.

Trexquant Investment LP raised its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 71.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 268,666 shares of the biopharmaceutical company's stock after buying an additional 112,010 shares during the quarter. Trexquant Investment LP owned approximately 0.28% of Ultragenyx Pharmaceutical worth $9,728,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD grew its holdings in Ultragenyx Pharmaceutical by 28.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,218,942 shares of the biopharmaceutical company's stock valued at $116,559,000 after buying an additional 706,519 shares during the period. Federated Hermes Inc. grew its holdings in shares of Ultragenyx Pharmaceutical by 0.3% during the 1st quarter. Federated Hermes Inc. now owns 2,055,200 shares of the biopharmaceutical company's stock worth $74,419,000 after purchasing an additional 5,400 shares during the period. Deutsche Bank AG grew its holdings in shares of Ultragenyx Pharmaceutical by 0.5% during the 1st quarter. Deutsche Bank AG now owns 1,701,493 shares of the biopharmaceutical company's stock worth $61,611,000 after purchasing an additional 8,385 shares during the period. Vestal Point Capital LP grew its holdings in shares of Ultragenyx Pharmaceutical by 100.0% during the 4th quarter. Vestal Point Capital LP now owns 1,500,000 shares of the biopharmaceutical company's stock worth $63,105,000 after purchasing an additional 750,000 shares during the period. Finally, Alyeska Investment Group L.P. grew its holdings in shares of Ultragenyx Pharmaceutical by 23.1% during the 4th quarter. Alyeska Investment Group L.P. now owns 1,439,740 shares of the biopharmaceutical company's stock worth $60,570,000 after purchasing an additional 269,733 shares during the period. Hedge funds and other institutional investors own 97.67% of the company's stock.

Insider Activity

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the company's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $37.39, for a total value of $89,922.95. Following the transaction, the director directly owned 15,344 shares of the company's stock, valued at $573,712.16. This represents a 13.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 5.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

RARE has been the subject of a number of research reports. Wells Fargo & Company decreased their target price on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a report on Thursday, July 10th. Cantor Fitzgerald decreased their target price on Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating for the company in a report on Wednesday, August 6th. HC Wainwright upgraded Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 target price for the company in a report on Monday, July 28th. Canaccord Genuity Group decreased their target price on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a report on Friday, August 8th. Finally, Guggenheim reiterated a "buy" rating and set a $64.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, June 20th. Eleven analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $81.50.

Ultragenyx Pharmaceutical Price Performance

NASDAQ RARE traded down $0.34 on Monday, reaching $29.96. The company had a trading volume of 1,340,019 shares, compared to its average volume of 1,472,288. The firm has a market capitalization of $2.89 billion, a PE ratio of -5.42 and a beta of 0.21. Ultragenyx Pharmaceutical Inc. has a 1 year low of $25.81 and a 1 year high of $60.37. The firm has a 50-day moving average of $30.83 and a 200-day moving average of $35.06.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, topping analysts' consensus estimates of ($1.27) by $0.10. The firm had revenue of $166.50 million during the quarter, compared to analysts' expectations of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.Ultragenyx Pharmaceutical's quarterly revenue was up 13.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.52) EPS. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.